GlaxoSmithKline Lowered to Underperform at Credit Suisse (GSK)
GlaxoSmithKline (NYSE:GSK) was downgraded by Credit Suisse from a “neutral” rating to an “underperform” rating in a research note issued on Thursday, TheFlyOnTheWall.com reports.
GlaxoSmithKline (NYSE:GSK) opened at 49.31 on Thursday. GlaxoSmithKline has a 52 week low of $41.68 and a 52 week high of $54.00. The stock’s 50-day moving average is $51.02 and its 200-day moving average is $50.94. The company has a market cap of $119.5 billion and a price-to-earnings ratio of 18.76.
GlaxoSmithKline (NYSE:GSK) last released its earnings data on Wednesday, July 24th. The company reported $0.26 earnings per share for the quarter, meeting the analysts’ consensus estimate of $0.26. The company had revenue of $6.62 billion for the quarter. GlaxoSmithKline’s revenue was up 5.5% compared to the same quarter last year. Analysts expect that GlaxoSmithKline will post $3.61 EPS for the current fiscal year.
A number of other analysts have also recently weighed in on GSK. Analysts at Citigroup Inc. downgraded shares of GlaxoSmithKline from a “buy” rating to a “neutral” rating in a research note to investors on Tuesday, September 10th. Separately, analysts at Cowen and Company upgraded shares of GlaxoSmithKline from a “market perform” rating to an “outperform” rating in a research note to investors on Wednesday, August 21st. Finally, analysts at Morgan Stanley downgraded shares of GlaxoSmithKline from an “equal weight” rating to an “underweight” rating in a research note to investors on Thursday, August 15th. Three research analysts have rated the stock with a sell rating, five have given a hold rating and six have given a buy rating to the company’s stock. GlaxoSmithKline currently has a consensus rating of “Hold” and a consensus target price of $87.60.
GlaxoSmithKline plc (NYSE:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.